These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 9295036

  • 1. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors.
    Wen T, Kono K, Shahinian A, Kiessling R, Mak TW, Klein G.
    Eur J Immunol; 1997 Aug; 27(8):1988-93. PubMed ID: 9295036
    [Abstract] [Full Text] [Related]

  • 2. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH.
    Cell Immunol; 2001 May 25; 210(1):56-65. PubMed ID: 11485353
    [Abstract] [Full Text] [Related]

  • 3. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
    Cayeux S, Beck C, Aicher A, Dörken B, Blankenstein T.
    Eur J Immunol; 1995 Aug 25; 25(8):2325-31. PubMed ID: 7545119
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S, Richter G, Becker C, Beck C, Aicher A, Pezzutto A, Dörken B, Blankenstein T.
    Eur J Immunol; 1997 Jul 25; 27(7):1657-62. PubMed ID: 9247574
    [Abstract] [Full Text] [Related]

  • 8. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY.
    J Immunol; 1987 Jun 15; 138(12):4515-23. PubMed ID: 3108394
    [Abstract] [Full Text] [Related]

  • 9. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
    Cerundolo V, Lahaye T, Horvath C, Zanovello P, Collavo D, Engers HD.
    Eur J Immunol; 1987 Feb 15; 17(2):173-8. PubMed ID: 3030766
    [Abstract] [Full Text] [Related]

  • 10. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice.
    Li Y, Newby SA, Johnston JV, Hellström KE, Chen L.
    J Immunol; 1995 Dec 15; 155(12):5705-10. PubMed ID: 7499857
    [Abstract] [Full Text] [Related]

  • 15. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

  • 16. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
    McIntosh JK, Mulé JJ, Travis WD, Rosenberg SA.
    Cancer Res; 1990 Apr 15; 50(8):2463-9. PubMed ID: 2317830
    [Abstract] [Full Text] [Related]

  • 17. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
    Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM.
    J Immunol; 1997 Nov 15; 159(10):4665-75. PubMed ID: 9366389
    [Abstract] [Full Text] [Related]

  • 18. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E, Xu Z, Bausero MA, Dancisak BB, Gorden KB, Davis G, Gray GS, Orchard PJ, Blazar BR.
    Cancer Gene Ther; 1995 Mar 15; 2(1):39-46. PubMed ID: 7542553
    [Abstract] [Full Text] [Related]

  • 19. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 20. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A, Shiku H, Nakayama E.
    J Immunol; 1993 Jun 01; 150(11):4900-10. PubMed ID: 8496592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.